Pertinax provides sustained, controlled antimicrobial protection for medical devices, biomaterials and in topical formulations.
Pertinax Pharma are supported by an experienced management team and a highly skilled and versatile team of scientists.
Get in touch to learn more about our technology and to discuss how Pertinax might be used in your products.
Get In Touch
About Pertinax Pharma
Pertinax formed in 2015, as a spin-out from the University of Bristol. The technology was initially developed in the laboratory of Dr Michele Barbour, CEO. Michele is supported by an experienced management team and a dynamic and dedicated team of scientists.
Find out the latest news and information from Pertinax.
Pertinax Pharma are delighted to announce that Simon Hubbert has joined the Board of Directors as Non- Executive Chairman. Simon has over 25 years’ experience in the medical device industry and has held CEO, senior commercial and … Read More about Pertinax appoint Simon Hubbert as Chairman
Team Pertinax were very proud to visit our PhD student Matthew Skeats at the University of Bristol's fantastic Research Without Borders public engagement event yesterday. Matt, who is also supported by the Industrial Challenge Strategy … Read More about Congrats to Matt!
We are delighted to have received notification that our EU patent has been granted. Our substance of matter patent protects Pertinax materials without reference to particular applications, and as such forms the strongest patent protection … Read More about European patent granted!